Cerliponase alfa ▼ is not registered in all countries, and where it is registered the content of its indication along with other content may vary.
Please refer to your local prescribing information before prescribing cerliponase alfa.
▼ This medicinal product is subject to additional monitoring, special reporting is required in relation to adverse reactions. Email us at medinfo@bmrn.com for further details.
Welcome to the resources home page, you will find a collection of materials designed to support your clinical practice- navigate through the different sections to explore up-to-date publications, clinical tools, insights, and educational content developed for healthcare professionals. Stay informed on the latest advancements and catch up on demand content from recent events.
On Demand
Navigating CLN2 diagnosis – the importance of testing: Dr Fumić discusses how to achieve an early diagnosis, with tips and advice on key diagnostic tests, CLN2 disease biomarkers and the future of newborn screening.
CLN2 Masterclass 2024 is a promotional BOME, speakers paid honorarium, deriving from clinical experience, individual cases may wary and consent in place.
On Demand
How to raise suspicion of CLN2: Dr Prpić uses a patient case study to illustrate the hallmark symptoms of CLN2 disease, and discusses diagnostic testing, differential diagnoses and strategies to achieve an early diagnosis.
CLN2 Masterclass 2024 is a promotional BOME, speakers paid honorarium, deriving from clinical experience, individual cases may wary and consent in place.
On Demand
Navigating CLN2 diagnosis: Dr Ram shares insights from his UK hospital on managing the complexities of CLN2 disease, communicating the diagnosis, providing structured support for patients and family, and the vital role of the multidisciplinary team.
CLN2 Masterclass 2024 is a promotional BOME, speakers paid honorarium, deriving from clinical experience, individual cases may wary and consent in place.
On Demand
Clinical manifestations of CLN2 disease: Dr Magner discusses what we know about CLN2 disease so far, including the natural history and key clinical assessments.
CLN2 Masterclass 2024 is a promotional BOME, speakers paid honorarium, deriving from clinical experience, individual cases may wary and consent in place.
On Demand
Atypical manifestations of CLN2 disease: Dr Dinopoulos provides an overview of atypical CLN2 disease, featuring patient case studies and a diagnostic protocol to facilitate early recognition.
CLN2 Masterclass 2024 is a promotional BOME, speakers paid honorarium, deriving from clinical experience, individual cases may wary and consent in place.
On Demand
Atypical manifestations of CLN2 disease: Prof Schulz shares patient case studies which highlight signs and symptoms of atypical CLN2 disease.
CLN2 Masterclass 2024 is a promotional BOME, speakers paid honorarium, deriving from clinical experience, individual cases may wary and consent in place.
Resources
Video
Prof Angela Schulz, Steering Committee Chair, welcomes you to LYNK: the Lysosomal and NCL Insights and Knowledge-sharing Network. This is a global initiative to connect specialists, treatment centres and referral networks to optimise long-term care for patients with CLN2.
On Demand
Welcome to this inaugural LYNK webinar with Professor Angela Schulz and an esteemed global faculty to discuss transitioning patients with CLN2 disease from paediatric to adolescent care, with practical guidance on meeting the evolving needs of patients and working effectively with caregivers and care teams to navigate the process.
On Demand
Dr Ram explains the importance of early recognition of CLN2 disease – its key signs and symptoms, how best to support the diagnostic journey, and the benefits of early intervention on patient outcomes.
On Demand
Prof Schulz reviews the challenges and benefits of long-term treatment with cerliponase alfa, management of atypical CLN2 phenotypes, and the role of newborn screening in achieving early, ideally pre-symptomatic intervention in CLN2 disease.
On Demand
During this webinar, first broadcast at the BioMarin sponsored CLN2 Masterclass 2021, Professor Stéphane Auvin from the Robert Debré University Hospital & Université de Paris, Paris, France, focusses on treatable infantile epilepsy (with a particular focus about myoclonic epilepsies), how to identify them and how to diagnose as early as possible.
Infographic
On Demand
On Demand
On Demand